Gilead Sciences (GILD +5.9%) trades higher after investors further digest the ramifications of...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD +5.9%) trades higher after investors further digest the ramifications of its mega-acquisition of Pharmasset (VRUS -0.1%) that sent shares skittishly lower yesterday. Citi took a look at the deal, deciding to upgrade GILD to Buy from Neutral, seeing a potential for the now-bigger company to dominate the Hepatitis C treatment market.